STAT | Reporting from the frontiers of health and medicine Follow STAT+: Breast cancer pill from AstraZeneca misses mark in pivotal trial A pill from AstraZeneca failed to improve outcomes in closely watched breast cancer study, a result that could limit the use of the medicine. https://www.statnews.com/2026/09/12/astrazeneca-breast-cancer-camizestrant-etcamah-serena-4-trail-failure/ statnews.com
